In the past week, ENTA stock has gone down by -1.06%, with a monthly gain of 13.87% and a quarterly plunge of -21.71%. The volatility ratio for the week is 5.72%, and the volatility levels for the last 30 days are 5.14% for Enanta Pharmaceuticals Inc The simple moving average for the past 20 days is 5.35% for ENTA’s stock, with a -7.80% simple moving average for the past 200 days.
Is It Worth Investing in Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Right Now?
Additionally, the 36-month beta value for ENTA is 0.57. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENTA is 19.70M and currently, short sellers hold a 15.16% ratio of that float. The average trading volume of ENTA on October 25, 2024 was 165.21K shares.
ENTA) stock’s latest price update
The stock price of Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dropped by -4.71 compared to previous close of 12.75. Despite this, the company has seen a fall of -1.06% in its stock price over the last five trading days. zacks.com reported 2024-10-02 that Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Analysts’ Opinion of ENTA
Many brokerage firms have already submitted their reports for ENTA stocks, with JP Morgan repeating the rating for ENTA by listing it as a “Underweight.” The predicted price for ENTA in the upcoming period, according to JP Morgan is $14 based on the research report published on August 09, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see ENTA reach a price target of $18, previously predicting the price at $49. The rating they have provided for ENTA stocks is “Hold” according to the report published on August 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to ENTA, setting the target price at $56 in the report published on December 09th of the previous year.
ENTA Trading at 2.47% from the 50-Day Moving Average
After a stumble in the market that brought ENTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.74% of loss for the given period.
Volatility was left at 5.14%, however, over the last 30 days, the volatility rate increased by 5.72%, as shares surge +16.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.01% upper at present.
During the last 5 trading sessions, ENTA fell by -1.06%, which changed the moving average for the period of 200-days by +2.36% in comparison to the 20-day moving average, which settled at $11.53. In addition, Enanta Pharmaceuticals Inc saw 29.12% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTA starting from Rottinghaus Scott T., who sale 5,375 shares at the price of $17.08 back on Jul 15 ’24. After this action, Rottinghaus Scott T. now owns 21,717 shares of Enanta Pharmaceuticals Inc, valued at $91,805 using the latest closing price.
Rottinghaus Scott T., the Chief Medical Officer of Enanta Pharmaceuticals Inc, sale 4,299 shares at $15.07 during a trade that took place back on Jul 11 ’24, which means that Rottinghaus Scott T. is holding 23,988 shares at $64,786 based on the most recent closing price.
Stock Fundamentals for ENTA
Current profitability levels for the company are sitting at:
- -1.71 for the present operating margin
- 0.96 for the gross margin
The net margin for Enanta Pharmaceuticals Inc stands at -1.6. The total capital return value is set at -0.36. Equity return is now at value -59.64, with -25.80 for asset returns.
Based on Enanta Pharmaceuticals Inc (ENTA), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is -19.25.
Currently, EBITDA for the company is -123.48 million with net debt to EBITDA at -1.69. When we switch over and look at the enterprise to sales, we see a ratio of 6.22. The receivables turnover for the company is 1.77for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.92.
Conclusion
In conclusion, Enanta Pharmaceuticals Inc (ENTA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
